.jetcityimage/iStock Editorial using Getty Images Morgan Stanley has actually opted for Eli Lilly (NYSE: LLY) as its own leading biopharma selection for 2025 and ranked another nine names in the area as over weight. The investment financial institution said in a note that it continues to feel “diabesity is actually readied to become.